Stock Track | Kymera Therapeutics Plunges 7.37% in Pre-Market After Q4 Earnings Miss Estimates

Stock Track

Feb 26

Kymera Therapeutics, Inc. (KYMR) experienced a sharp pre-market decline of 7.37% on Thursday. The biopharmaceutical company's stock moved lower ahead of the market open following the release of its latest financial results.

The decline comes after Kymera Therapeutics reported fourth-quarter 2025 results that significantly missed analyst expectations. The company posted a loss of $0.97 per share, falling short of the consensus estimate of a $0.78 loss. Revenue for the quarter came in at $2.871 million, a dramatic miss compared to the $14.798 million analysts had anticipated and representing a 61.17% decrease from the same period last year.

Kymera's net loss widened to $86.981 million for the quarter, compared to losses in the prior year period. The company noted that research and development expenses increased due to investment in its STAT6 program and discovery initiatives. Despite the disappointing quarterly results, Kymera ended 2025 with $1.6 billion in cash, cash equivalents and investments, which management stated provides a cash runway into 2029.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1142458737"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142458737\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142458737?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142458737","market":"nz","top_or_hot":-1,"title":"Stock Track | Kymera Therapeutics Plunges 7.37% in Pre-Market After Q4 Earnings Miss Estimates","media":"Stock Track","content":"<p>Kymera Therapeutics, Inc. (KYMR) experienced a sharp pre-market decline of 7.37% on Thursday. The biopharmaceutical company's stock moved lower ahead of the market open following the release of its latest financial results.</p><p>The decline comes after Kymera Therapeutics reported fourth-quarter 2025 results that significantly missed analyst expectations. The company posted a loss of $0.97 per share, falling short of the consensus estimate of a $0.78 loss. Revenue for the quarter came in at $2.871 million, a dramatic miss compared to the $14.798 million analysts had anticipated and representing a 61.17% decrease from the same period last year.</p><p>Kymera's net loss widened to $86.981 million for the quarter, compared to losses in the prior year period. The company noted that research and development expenses increased due to investment in its STAT6 program and discovery initiatives. Despite the disappointing quarterly results, Kymera ended 2025 with $1.6 billion in cash, cash equivalents and investments, which management stated provides a cash runway into 2029.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kymera Therapeutics Plunges 7.37% in Pre-Market After Q4 Earnings Miss Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kymera Therapeutics Plunges 7.37% in Pre-Market After Q4 Earnings Miss Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 20:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kymera Therapeutics, Inc. (KYMR) experienced a sharp pre-market decline of 7.37% on Thursday. The biopharmaceutical company's stock moved lower ahead of the market open following the release of its latest financial results.</p><p>The decline comes after Kymera Therapeutics reported fourth-quarter 2025 results that significantly missed analyst expectations. The company posted a loss of $0.97 per share, falling short of the consensus estimate of a $0.78 loss. Revenue for the quarter came in at $2.871 million, a dramatic miss compared to the $14.798 million analysts had anticipated and representing a 61.17% decrease from the same period last year.</p><p>Kymera's net loss widened to $86.981 million for the quarter, compared to losses in the prior year period. The company noted that research and development expenses increased due to investment in its STAT6 program and discovery initiatives. Despite the disappointing quarterly results, Kymera ended 2025 with $1.6 billion in cash, cash equivalents and investments, which management stated provides a cash runway into 2029.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYMR","symbol_name":"Kymera Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1142458737","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142458737","pubTimestamp":1772110054,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Kymera Therapeutics, Inc. (KYMR) experienced a sharp pre-market decline of 7.37% on Thursday. The biopharmaceutical company's stock moved lower ahead of the market open following the release of its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KYMR":"Kymera Therapeutics, Inc."},"translate_title":"个股追踪|Kymera Therapeutics Q4盈利不及预期盘前暴跌7.37%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYMR":1},"content_text":"Kymera Therapeutics, Inc. (KYMR) experienced a sharp pre-market decline of 7.37% on Thursday. The biopharmaceutical company's stock moved lower ahead of the market open following the release of its latest financial results.The decline comes after Kymera Therapeutics reported fourth-quarter 2025 results that significantly missed analyst expectations. The company posted a loss of $0.97 per share, falling short of the consensus estimate of a $0.78 loss. Revenue for the quarter came in at $2.871 million, a dramatic miss compared to the $14.798 million analysts had anticipated and representing a 61.17% decrease from the same period last year.Kymera's net loss widened to $86.981 million for the quarter, compared to losses in the prior year period. The company noted that research and development expenses increased due to investment in its STAT6 program and discovery initiatives. Despite the disappointing quarterly results, Kymera ended 2025 with $1.6 billion in cash, cash equivalents and investments, which management stated provides a cash runway into 2029.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}